Amgen, Inc. ( NASDAQ: AMGN) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call February 12, 2025 11:20 AM ET Narimon Honarpour - Senior Vice President, Global Development Justin Claeys - ...

As with Epogen, the initial discoveries that laid the basis for the drug had ... That decade of investment and research was paying off. In 1992, Amgen hit the billion dollars sales mark and ...

Story Feb. 13 - Encoded Therapeutics: The gene therapy biotech is laying off 29% of staffers as it focuses ... by 40% and reassessing the future of Amgen-partnered T-cell engager CX-904 as a ...

Eye-disease-focused Acelyrin will be absorbed into immune-mediated disease specialist Alumis as part of an all-stock merger.

Verizon's dividend yield and Merck’s growth lead the Dow Dogs. Read why they’re set for solid returns, with other top picks ...

The week's investing action plan includes a strong dose of pharma and biotech earnings, January econ reports, plus Amazon and Alphabet.

Pieri has held leadership positions for Bristol Myers Squibb, Janssen, Amgen, Daiichi Sankyo and ... and Albertsons is laying off more than 150 Safeway corporate workers. Inside Beauty spoke ...

By identifying these cells and their role, we hope to uncover new therapeutic targets and lay the groundwork for more ...

One of the best iron players in the world, he’s laid the foundations of a reliable ... “He’s comfortable off the tee. He drives it very straight. He’s turned into a really, really, really ...

Free cash flow surged to $4.4 billion, up a remarkable 1,367% year over year. Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth.

Elsewhere, cell therapy developer Turnstone Biologics announced a second round of layoffs and plans to explore “strategic alternatives.” ...